The FDA acceptance of the NDA for Pixclara is a significant regulatory milestone that increases the likelihood of approval by the PDUFA date. This could lead to commercialization in a high-unmet-need oncology indication, potentially driving revenue growth. Traders should monitor for any updates on the approval process and consider the potential market opportunity for glioma imaging.
Price Chart
Executive Summary
Telix Pharmaceuticals announced that the FDA has accepted the resubmitted New Drug Application (NDA) for TLX101-Px (Pixclara), a PET imaging agent for glioma, with a PDUFA goal date of September 11, 2026. This is a significant milestone in the company's pipeline.
Key Facts
- FDA accepted the resubmitted NDA for TLX101-Px (Pixclara) for the imaging of glioma
- PDUFA goal date set for September 11, 2026
- TLX101-Px has been granted Orphan Drug and Fast Track designations by the FDA
- Approval would fulfill an unmet medical need for characterizing recurrent or progressive glioma
- No revenue contribution from TLX101-Px is included in Telix's FY 2026 financial guidance
Financial Impact
Potential future revenue from a new oncology product, though not included in current guidance
Risk Factors
- Approval not guaranteed by PDUFA date
- No revenue contribution included in current financial guidance
- Potential competition in the radiopharmaceutical space
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-024572 |
| Document: a20260410pixclarandaacce.htm | 0001628280-26-024572 |
| Document: 0001628280-26-024572-index-headers.html | 0001628280-26-024572 |
| Document: 0001628280-26-024572-index.html | 0001628280-26-024572 |
| Document: 0001628280-26-024572.txt | 0001628280-26-024572 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 21, 2026 22w ago | 6-K | $9.75 $11.50 | ▲ +17.95% | ▲ +14.76% | $8.82 (−9.54%) |
May 18, 2026 23w ago | 3 | $9.75 $11.69 | ▲ +19.94% | ▲ +13.65% | $8.82 (−9.54%) |
May 18, 2026 23w ago | 3 | $9.75 $11.69 | ▲ +19.94% | ▲ +13.65% | $8.82 (−9.54%) |
May 18, 2026 23w ago | 3 | $9.75 $11.69 | ▲ +19.94% | ▲ +13.65% | $8.82 (−9.54%) |
Apr 21, 2026 27w ago | 6-K | $10.50 $10.50 | · 0.00% | ▼ −4.78% | $8.82 (−16.00%) |
Apr 14, 2026 28w ago | 6-K | $10.57 $11.50 | ▲ +8.80% | ▲ +0.28% | $8.82 (−16.56%) |
Apr 13, 2026 28w ago | 6-K | $10.57 $11.50 | ▲ +8.80% | ▲ +0.28% | $8.82 (−16.56%) |
Apr 9, 2026 28w ago | 6-K | $9.70 $11.45 | ▲ +18.04% | ▲ +7.71% | $8.82 (−9.08%) |
Apr 8, 2026 28w ago | 6-K | $9.70 $12.30 | ▲ +26.80% | ▲ +16.02% | $8.82 (−9.08%) |
Apr 7, 2026 29w ago | 6-K | $9.00 $11.88 | ▲ +31.94% | ▲ +18.67% | $8.82 (−2.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers